Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report sent to investors on Tuesday,Benzinga reports. The firm currently has a $16.00 price target on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective on the stock. JMP Securities restated a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $1.77 on Tuesday. Esperion Therapeutics has a 12 month low of $1.57 and a 12 month high of $3.94. The company has a 50-day moving average of $2.00 and a 200-day moving average of $2.09. The company has a market cap of $348.75 million, a P/E ratio of -2.77 and a beta of 1.01.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio acquired a new position in shares of Esperion Therapeutics during the third quarter valued at $606,000. Anson Funds Management LP acquired a new position in Esperion Therapeutics during the third quarter worth about $540,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after acquiring an additional 295,378 shares during the period. Wellington Management Group LLP boosted its position in shares of Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after purchasing an additional 241,512 shares during the period. Finally, Wasatch Advisors LP boosted its position in shares of Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the period. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.